Abstract CT022: Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study
Year: 2023
Type: conference-abstract
Source: Cancer Research
Institutions: Universitätsklinikum Würzburg, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, CHU Dinant Godinne UCL Namur, Paracelsus Medical University, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Duran i Reynals Hospital, Universitat de Barcelona, The Maria Sklodowska-Curie National Research Institute of Oncology, University of Liverpool, University of Perugia, Azienda Ospedaliera S.Maria, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, The Ohio State University, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Semmelweis University, Centre Hospitalier Universitaire de Clermont-Ferrand, MorphoSys (Germany), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4365514092